Methods for treating or ameliorating a melanoma and killing melanoma cells
The invention provides novel compositions—lipopeptides and analogs, including somocystinamide A, and somocystinamide A variants and analogs, and pharmaceutical compositions, liposomes and nanoparticles comprising them, and methods of making and using them. In one embodiment, these lipopeptides and analogs are used to induce apoptosis in a cell, which can be a normal cell, a dysfunctional cell and/or a cancer (tumor) cell. In alternative embodiments, the compositions of the invention, including the lipopeptides and analogs of the invention, and the pharmaceutical compositions comprising them, are used to treat or ameliorate (including slowing the progression of) normal, dysfunctional (e.g., abnormally proliferating) and/or tumor associated blood vessels, including endothelial and/or capillary cell growth; including neovasculature related to (within, providing a blood supply to) a tumor.
1. A method for killing a melanoma cancer cell comprising:
contacting the melanoma cancer cell with a somocystinamide A.
2. The method of claim 1 , wherein the melanoma cancer cell is a cutaneous or intraocular melanoma cell.
3. The method of claim 1 , wherein the somocystinamide A is formulated as a nanoparticle, or a liposomal nanoparticle.
4. The method of claim 1 , wherein the somocystinamide A is formulated as a liposome or a multilayered liposome.
5. The method of claim 4 , wherein the liposome is about 100 nM in size.
6. The method of claim 1 , wherein the somocystinamide A, is administered with compound selected from the group consisting of: a thrombospondin, an angiostatin 5, a pigment epithelium-derived factor, an angiotensin, a laminin peptide, a fibronectin peptide, a plasminogen activator inhibitor, a tissue metalloproteinase inhibitor, an interferon, an interleukin 12, a platelet factor 4, an IP-10, a Gro-β, a thrombospondin, a 2-methoxyoestradiol, a proliferin-related protein, a carboxiamidotriazole, a marimastat, a pentosan polysulphate, an angiopoietin 2, an interferon-alpha, a herbimycin A, a sulfonated distamycin A derivative, a 16K prolactin fragment, a linomide, a thalidomide, a pentoxifylline, a genistein, a TNP-470, an endostatin, a paclitaxel, a docetaxel, a polyamine, a proteasome inhibitor, a kinase inhibitor, a signaling peptide, an accutin, a cidofovir, a vincristine, a bleomycin, a platelet factor 4, a minocycline, a 1,2-dithiol-3-thione, and any combination thereof.
7. The method of claim 1 , wherein the somocystinamide A is formulated as a pharmaceutical composition, or is formulated with a pharmaceutically acceptable carrier.
8. The method of claim 7 , wherein the pharmaceutical composition is administered parenterally, topically, orally, by local administration, by aerosol or transdermally.
9. The method of claim 7 , wherein the pharmaceutical composition is formulated for human or veterinary use.
10. The method of claim 7 , wherein the pharmaceutical composition is formulated in a unit dosage form.
11. The method of claim 10 , wherein the unit dosage form comprises a tablet, a pill, a powder, a dragee, a capsule, a liquid, a lozenge, a soft sealed capsule, a gel, a syrup, a slurry, an aerosol or a suspension.
12. The method of claim 7 , wherein the pharmaceutical composition is formulated as an aqueous suspension or an oil-based suspension, a liquid, a powder, an emulsion, a lyophilized powder, a spray, a cream, a lotion, a controlled release formulation, a tablets, a pill, a gel, on patch, or in an implant.
13. The method of claim 7 , wherein the pharmaceutical composition is administered topically by applicator stick, solution, suspension, emulsion, gel, cream, ointment, paste, jelly, paint, powder or aerosol.
14. A method for treating, ameliorating, or slowing the progression of, a melanoma in an individual in need thereof, comprising administering a pharmaceutical composition comprising a somocystinamide A.
15. The method of claim 14 , wherein the somocystinamide A is formulated as a liposome or a multilayered liposome.
16. The method of claim 14 , wherein the somocystinamide A, is administered with compound selected from the group consisting of: a thrombospondin, an angiostatin 5, a pigment epithelium-derived factor, an angiotensin, a laminin peptide, a fibronectin peptide, a plasminogen activator inhibitor, a tissue metalloproteinase inhibitor, an interferon, an interleukin 12, a platelet factor 4, an IP-10, a Gro-β, a thrombospondin, a 2-methoxyoestradiol, a proliferin-related protein, a carboxiamidotriazole, a marimastat, a pentosan polysulphate, an angiopoietin 2, an interferon-alpha, a herbimycin A, a sulfonated distamycin A derivative, a 16K prolactin fragment, a linomide, a thalidomide, a pentoxifylline, a genistein, a TNP-470, an endostatin, a paclitaxel, a docetaxel, a polyamine, a proteasome inhibitor, a kinase inhibitor, a signaling peptide, an accutin, a cidofovir, a vincristine, a bleomycin, a platelet factor 4, a minocycline, a 1,2-dithiol-3-thione, and any combination thereof.
17. The method of claim 14 , wherein the pharmaceutical composition is administered parenterally, topically, orally, by local administration, by aerosol or transdermally.
18. The method of claim 17 , wherein the pharmaceutical composition is administered topically by applicator stick, solution, suspension, emulsion, gel, cream, ointment, paste, jelly, paint, powder or aerosol.
19. The method of claim 14 , wherein the pharmaceutical composition is formulated as an aqueous suspension or an oil-based suspension, a liquid, a powder, an emulsion, a lyophilized powder, a spray, a cream, a lotion, a controlled release formulation, a tablets, a pill, a gel, on patch, or in an implant.
20. The method of claim 14 , wherein the pharmaceutical composition is formulated for human or veterinary use.